ReBio Pharma Relaunches with Strategic Focus on Ocular Oncology as Lead Program Nears the Clinic

Turku, Finland and Geneva, Switzerland, 17 November 2025 – ReBio Pharma (“ReBio” or “the Company”), a biotechnology company developing novel, targeted, vision-preserving therapies, today announced a strategic transformation to focus on ocular oncology, with its lead uveal melanoma program advancing toward clinical trials and world-class advisors joining to guide the development pathway. 

The Company is addressing one of oncology's most challenging areas – primary eye cancers, where current treatments often sacrifice vision to control disease. Powered by its proprietary SiSu® therapeutic amplifier technology, ReBio is pioneering a new class of ocular therapies that achieve precise, programmable drug exposure at the site of disease while minimising systemic toxicity. The initial focus is uveal melanoma, the most common primary eye cancer in adults and an area with no approved medical therapy. 

Advancing Toward Clinical Trials with RBP-01

ReBio's lead program, RBP-01, applies the Company's proprietary SiSu® therapeutic amplifier technology to achieve potent, localized tumor control in uveal melanoma. RBP-01 is a novel targeted therapy designed for programmable exposure, reaching high therapeutic concentrations with minimal off-target toxicity. The program is expected to enter the clinic in Q1 2026 as a first-in-class, vision-preserving treatment.

Building on the validated biology of PKC inhibition in uveal melanoma, RBP-01 achieves dramatically higher ocular concentrations through localized intravitreal injection. This targeted approach aims to maintain an optimal safety profile, preserve vision and enable efficient tumor control.

Preclinical Research Selected for Oral Presentation

The Company's preclinical research has been selected for oral presentation at an upcoming major medical conference. This recognition highlights the potential of ReBio's precision chemistry platform to address longstanding challenges in ocular oncology treatment.

World-Renowned Experts Join Scientific Advisory Board

ReBio has assembled exceptional clinical expertise to guide its development programs:

• Professor Mandeep Sagoo, Professor of Ophthalmology and Ocular Oncology at UCL Institute of Ophthalmology and Consultant Ophthalmic Surgeon at Moorfields Eye Hospital and St. Bartholomew's Hospital, brings extensive expertise in treating adult and pediatric eye tumors. A Fulbright Scholar, Professor Sagoo has authored over 100 academic papers and serves as Honorary Secretary of the International Society of Ocular Oncology. 
• Professor Ido (Didi) Fabian, Principal Investigator of the Global Retinoblastoma Study Group and consultant ocular oncologist at Sheba Medical Center, leads the world's largest collaborative network in pediatric ocular oncology. As founder of this groundbreaking initiative encompassing over 150 countries, Professor Fabian has transformed understanding of global disparities in retinoblastoma care.

ReBio is also collaborating with Professor Paul Nathan, a leading oncologist at Mount Vernon Cancer Centre, as a consultant to support the Company’s portfolio expansion. With deep expertise in melanoma and immuno-oncology, Professor Nathan played a pivotal role in the development of tebentafus, the first therapy to demonstrate a survival benefit in metastatic uveal melanoma, marking a major advancement in treatment for this rare and aggressive cancer.

Building a Comprehensive Pipeline

Beyond RBP-01, ReBio is pursuing the development of additional assets targeting uveal melanoma and retinoblastoma, expanding therapeutic possibilities of existing treatments with targeted drug exposure. With SiSu® enabling rapid progression from concept to candidate, the company is shaping a development strategy that extends beyond current programs and into areas of high unmet need.